EIT Pharma
EIT Pharma develops therapies for infectious diseases with high unmet needs, including treatments for chronic hepatitis D and acute respiratory infections. It aims to advance therapies for patients who have few treatment options through an efficient drug-development process.
Facts
- HQ
- Kirkland, WA
- Sectors
- Biotechnology Research
- Employees
- 6
- Founders
- Jeffrey Glenn
Is this your organization? Claim it
EIT Pharma, led by ex-Athira CEO Leen Kawas, raises $35M Series A to advance lonafarnib for chronic hepatitis D
Kirkland-based EIT Pharma, led by former Athira CEO Leen Kawas, raised $35 million in an oversubscribed Series A led by Propel Bio Partners to support FDA review, manufacturing and commercial preparations for lonafarnib as an oral treatment candidate for chronic hepatitis D. The FDA accepted EIT Pharma's New Drug Application for lonafarnib on Aug. 11; the drug was acquired from Eiger BioPharmaceuticals' 2024 bankruptcy sale.
Leen Kawas returns as CEO of Kirkland’s EIT Pharma after 2021 Athira exit, to advance lonafarnib
Leen Kawas has returned to operations as CEO of Kirkland-based EIT Pharma after leaving Athira in 2021 and running Propel Bio Partners with investor Richard Kayne; she will lead the small infectious-disease biotech as it advances its lead drug lonafarnib toward data readouts while balancing travel and investment work. The company has about a dozen employees, occupies a coworking space in Kirkland, and expects to need new Seattle-area office space within a year.
People
-
Leen Kawas Executive, Chief Executive Officer
-
Xue Hua Executive, Chief Development Officer (CDO)